CA2155568A1 - Vecteurs exprimant un interferon humain pour le traitement du sida - Google Patents

Vecteurs exprimant un interferon humain pour le traitement du sida

Info

Publication number
CA2155568A1
CA2155568A1 CA002155568A CA2155568A CA2155568A1 CA 2155568 A1 CA2155568 A1 CA 2155568A1 CA 002155568 A CA002155568 A CA 002155568A CA 2155568 A CA2155568 A CA 2155568A CA 2155568 A1 CA2155568 A1 CA 2155568A1
Authority
CA
Canada
Prior art keywords
vector
cassette
hiv
ifn
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002155568A
Other languages
English (en)
French (fr)
Inventor
Majid Mehtali
Philippe Leissner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2155568A1 publication Critical patent/CA2155568A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002155568A 1993-12-13 1994-12-13 Vecteurs exprimant un interferon humain pour le traitement du sida Abandoned CA2155568A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR93/14915 1993-12-13
FR9314915A FR2713657B1 (fr) 1993-12-13 1993-12-13 Nouveaux vecteurs pour le traitement du sida.

Publications (1)

Publication Number Publication Date
CA2155568A1 true CA2155568A1 (fr) 1995-06-22

Family

ID=9453844

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002155568A Abandoned CA2155568A1 (fr) 1993-12-13 1994-12-13 Vecteurs exprimant un interferon humain pour le traitement du sida

Country Status (7)

Country Link
EP (1) EP0682712A1 (ja)
JP (1) JPH08506970A (ja)
AU (1) AU1275195A (ja)
CA (1) CA2155568A1 (ja)
FR (1) FR2713657B1 (ja)
SG (1) SG49230A1 (ja)
WO (1) WO1995016784A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004799A (en) * 1996-03-05 1999-12-21 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral DNA vaccines
EP0951544A2 (en) * 1996-07-03 1999-10-27 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
KR100776475B1 (ko) 2000-02-02 2007-11-16 안제스에무지 가부시키가이샤 유전자 전달을 위한 바이러스 엔벨로프 벡터
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
SG10202104509PA (en) * 2016-03-19 2021-06-29 Exuma Biotech Corp Methods and compositions for transducing lymphocytes and regulated expansion thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0266940B1 (en) * 1986-10-22 1992-12-16 Schering Corporation Use of recombinant human alpha interferon for the manufacture of a medicament for the treatment of aids virus
WO1990011359A1 (en) * 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
DE69230506T2 (de) * 1991-10-25 2000-06-21 Sidney Kimmel Cancer Center Sa Lymphokine gentherapie bei krebs in kombination mit tumorantigenen

Also Published As

Publication number Publication date
EP0682712A1 (fr) 1995-11-22
WO1995016784A1 (fr) 1995-06-22
FR2713657B1 (fr) 1996-03-01
FR2713657A1 (fr) 1995-06-16
SG49230A1 (en) 1998-05-18
JPH08506970A (ja) 1996-07-30
AU1275195A (en) 1995-07-03

Similar Documents

Publication Publication Date Title
JP2001517433A (ja) 非霊長類レンチウイルスベクターおよびパッケージングシステム
US20200165317A1 (en) Methods and compositions for protection against lentiviral infections
CA2155568A1 (fr) Vecteurs exprimant un interferon humain pour le traitement du sida
Mautino et al. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense
US6776986B1 (en) Inhibition of HIV-1 replication by antisense RNA expression
JP5324912B2 (ja) ＨＩＶＶｉｆ変異体
AU717233B2 (en) Inhibition of HIV-1 replication by antisense RNA expression
AU2003242496B2 (en) Conjugate
EP0682708B1 (fr) Composition de variants transdominants de proteines virales pour un effet antiviral
WO1996017071A1 (fr) Lignees cellulaires d'encapsidation pour la transcomplementation de vecteurs retroviraux defectifs
Kobinger et al. Enhancement of retroviral production from packaging cell lines expressing the human immunodeficiency type 1 VPU gene
Vera Ortega Approaching a Tat-Rev independent HIV-1 clone towards a model for research
JP2003500050A (ja) 改善されたベクターの選択方法
JP2016067306A (ja) ヒト免疫不全ウイルスの感染防御方法
WO1999000490A2 (en) Attenuated human immunodeficiency virus vaccine
JPH11514231A (ja) 細胞にｈｉｖ重感染に対する抵抗性を与える組成物および方法
Rainho Examining The Role of Nef in the Resistance of SIV-Infected Macrophages to CD8+ T Cell Suppression
Abravaya et al. Abimiku AG; Franchini G; Aldrich K; Myagkikh M; Markham P; Gard E; Gallo RC; Robert-Guroff M Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2. AIDS Res Hum Retroviruses 11: 383-93 (1995)
Gnanadurai Generation and characterization of SIVagmSab92018ivTF infectious molecular clone and its" HIV-1 like" derivative
Gnanadurai Generation and characterization of SIVagmSab infectious molecular clone and its" HIV-1 like" derivative
Choudhary Regulation of Human T-cell Leukemia Virus Type 1 Infection and Replication
ZA200107371B (en) Method for selecting improved vectors.

Legal Events

Date Code Title Description
FZDE Dead